Nirav Shah to Antigens, CD20
This is a "connection" page, showing publications Nirav Shah has written about Antigens, CD20.
Connection Strength
0.716
-
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020 10; 26(10):1569-1575.
Score: 0.680
-
Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Cytotherapy. 2018 03; 20(3):394-406.
Score: 0.035